

Novel idea: virulence-
based therapy
against helicobacter
pylori infection (smart
...

[Health & Medicine](#)



**ASSIGN
BUSTER**

Introduction

Helicobacter pylori (*H. pylori*) is a Gram-negative, spiral, and microaerophilic bacterium, which can usually persist lifelong in gastric mucosa if not treated efficiently. *H. pylori* infection plays an undeniable role in the development of different gastroduodenal diseases, while its eradication cures ulcer disease and also prevents occurrence of gastric cancer ([1](#) - [3](#)). At the beginning, as usual, it was thought that antibacterial therapy could easily eliminate the infection in human gastric mucosa. As such, during the last 30 years that we have known about *H. pylori* , there have been numerous therapeutic regimens suggested (e. g., sequential, triple/dual, quadruple, DANCE, hybrid, salvage, and empirical) ([4](#) - [8](#)). Therefore, many studies have been conducted to identify the most effective and least harmful therapeutic regimen, although, a unique therapeutic regimen to cure *H. pylori* infection in all reported colonized individuals is still lacking ([8](#) , [9](#)). However, high rates of resistance have been reported to all primary/secondary lines and even to the newly introduced alternative drugs described for *H. pylori* treatment ([10](#)). In 2014, due to the skyrocketing rates of antibiotics resistance, a new scope toward the antibiotic therapy against this mysterious bacterium seems necessary. It has been indicated that virulence factors are the ability of a bacterium to induce certain disease in attributed hosts ([1](#) , [11](#) , [12](#)). Accordingly, virulence factors in *H. pylori* (e. g., *cagA*, *dupA*, *homB* , and *vacA*) have essential and definite roles in pathogenesis of different gastroduodenal disorders such as chronic gastritis, gastric cancer, and peptic ulcers ([13](#) - [15](#)). Certain *H. pylori* strains (specific PCR positive for *cagA*, *dupA*, *homB* , and *vacA*) harboring virulence

determinants are capable to survive longer and induce more severe diseases. Surprisingly, among the currently described studies, no therapeutic regimen according to *H. pylori* virulence pattern (virutype) has yet been suggested.

Proposed Idea

Given the aforementioned problems in *H. pylori* treatment, it would be interesting if new therapeutic approaches can solve this complexity.

Accordingly, under condition of smart therapy, we propose an idea that suggests logical application of smart therapy against *H. pylori* strains that will reduce current distribution of antibiotic resistance and also increase efficacy of prescribed antibiotics. If a clinician knows about virutype and susceptibility pattern of *H. pylori* locally, it is easy to choose a therapeutic regimen (smart therapy) that will reliably cure most of infections during the first-line therapy. In clinical settings, by prescription of smart therapy, physicians can opt to not treat non-virulent strains found in symptomatic patients, which account for more than half of all subjects. If smart therapy is validated as a new therapeutic regimen, current therapeutic failures will be considerably reduced.

Evaluation of the Idea

In order to have a continuing effective therapeutic regimen against *H. pylori*, we practically suggest to first investigating virulence pattern (virutype) of the bacterium, therefore; antibiotic therapy should be considered only for virulent strains (smart therapy). Clinicians should only aim to detect virulent *H. pylori* according to the virulence genes, and then start to eradicate them

based on local antibiotic susceptibility pattern. Indeed, detection of such virulent strains (*vacA* +, *cagA* +, *homB* +, and *dupA* +), identified by the simple sensitive PCR method, can be the main inclusion criteria to start the next step. If so, as the second step (in the case of virulent *H. pylori* strain), we need to follow an updated antibiotic susceptibility profile, which indicates the most effective drugs for each region.

Discussion/Conclusion

Helicobacter pylori is inherently resistant to a few antibiotics (e. g., sulfonamides, trimethoprim, nalidixic acid, and vancomycin), and it will likely become resistant to metronidazole, clarithromycin, and fluoroquinolones, if these antibiotics are prescribed alone ([16](#), [17](#)). Given the significant presence of virulence factors in *H. pylori* pathogenesis and the direct link to cause more severe diseases, it is hypothesized that designation of therapeutic regimen according to virulence factors may help physicians to increase efficacy rate of therapy ([18](#)). The smart therapy strategy consists of two basic parts; (i) local antibiotic susceptibility tests and (ii) *H. pylori* virutype. The main advantage of smart therapy is its flexibility, which can give the possibility to clinicians for adjusting new antibiotics according to different localities in the world. As we already knew, antibiotic exposure is one of the main factors, which can push *H. pylori* to make new mutations, and can eventually result in more resistant genotypes. In essence, smart therapy can avoid from distribution of antibiotic resistance due to careful usage of its contained drugs for therapeutic regimens. Within smart therapy, the answer to the question of how resistant strains should be eradicated is to logically target virulent strains and smartly tackle those using effective

combinations of antibiotics. We therefore conclude that our idea can enable the possible application of smart therapy in clinical practice for symptomatic digestive diseases. According to the smart therapy, more studies of prescribed drugs and certain virulence genes are suggested to examine their potential to be incorporated as virutypes of *H. pylori*.

Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We thank Dr. Ronald Gorham for critical reading of the manuscript. The contents of this article are the sole responsibility of the authors and do not necessarily represent the official views of the companies or the funding agency.

References

1. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clin Microbiol Rev* (2006)19 (3): 449–90. doi: 10. 1128/CMR. 00054-05

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#)

2. Bastos J, Peleteiro B, Barros R, Alves L, Severo M, de Fátima Pina M, et al. Sociodemographic determinants of prevalence and incidence of *Helicobacter pylori* infection in Portuguese adults. *Helicobacter* (2013)18 (6): 413–22. doi: 10. 1111/hel. 12061

<https://assignbuster.com/novel-idea-virulence-based-therapy-against-helicobacter-pylori-infection-smart-therapy/>

[CrossRef Full Text](#)

3. Vilaichone RK, Mahachai V, Shiota S, Uchida T, Ratanachu-ek T, Tshering L, et al. Extremely high prevalence of *Helicobacter pylori* infection in Bhutan. *World J Gastroenterol* (2013)19 (18): 2806-10. doi: 10. 3748/wjg. v19. i18. 2806

[PubMed Abstract](#) | [PubMed Full Text](#) | [CrossRef Full Text](#)

4. Dore MP, Marras L, Maragkoudakis E, Nieddu S, Manca A, Graham DY, et al. Salvage therapy after two or more prior *Helicobacter pylori* treatment failures: the super salvage regimen. *Helicobacter* (2003)8 (4): 307-9. doi: 10. 1046/j. 1523-5378. 2003. 00150. x

[PubMed Abstract](#) | [PubMed Full Text](#) | [CrossRef Full Text](#)

5. Fuccio L, Zagari RM, Bazzoli F. What is the best salvage therapy for patients with *Helicobacter pylori* infection? *Nat Clin Pract Gastroenterol Hepatol* (2008)5 (11): 608-9. doi: 10. 1038/ncpgasthep1256

[CrossRef Full Text](#)

6. Roccarina D, Franceschi F, Zocco MA, Garcovich M, Gasbarrini G, Gasbarrini A. Different antibiotic no culture eradicating (DANCE) strategy: an easy way to manage *H. pylori* eradication. *Dig Liver Dis* (2012)44 (11): 889-92. doi: 10. 1016/j. dld. 2012. 05. 010

[CrossRef Full Text](#)

7. Tepes B, O'Connor A, Gisbert JP, O'Morain C. Treatment of *Helicobacter pylori* infection 2012. *Helicobacter* (2012)17 (Suppl 1): 36–42. doi: 10.1111/j.1523-5378.2012.00981.x

[CrossRef Full Text](#)

8. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of *Helicobacter pylori*: a multicentre, open-label, randomised trial. *Lancet* (2013)381 (9862): 205–13. doi: 10.1016/S0140-6736(12)61579-7

[PubMed Abstract](#) | [PubMed Full Text](#) | [CrossRef Full Text](#)

9. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. *Helicobacter pylori* resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut* (2013)62 (1): 34–42. doi: 10.1136/gutjnl-2012-302254

[PubMed Abstract](#) | [PubMed Full Text](#) | [CrossRef Full Text](#)

10. Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of *Helicobacter pylori* to levofloxacin and moxifloxacin in Iran. *Intern Emerg Med* (2012)7 (5): 447–52. doi: 10.1007/s11739-011-0563-1

[PubMed Abstract](#) | [PubMed Full Text](#) | [CrossRef Full Text](#)

11. Graham DY, Yamaoka Y. Disease-specific *Helicobacter pylori* virulence factors: the unfulfilled promise. *Helicobacter* (2000)5 (Suppl 1): S3-9. doi: 10.1046/j.1523-5378.2000.0050S1003.x

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#)

12. Lu H, Yamaoka Y, Graham DY. *Helicobacter pylori* virulence factors: facts and fantasies. *Curr Opin Gastroenterol* (2005)21 (6): 653-9. doi: 10.1097/01.mog.0000181711.04529.d5

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#)

13. Talebi Bezmin Abadi A, Rafiei A, Ajami A, Hosseini V, Taghvaei T, Jones KR, et al. *Helicobacter pylori* homB, but not cagA, is associated with gastric cancer in Iran. *J Clin Microbiol* (2011)49 (9): 3191-7. doi: 10.1128/JCM.00947-11

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#)

14. Abadi AT, Taghvaei T, Wolfram L, Kusters JG. Infection with *Helicobacter pylori* strains lacking dupA is associated with an increased risk of gastric ulcer and gastric cancer development. *J Med Microbiol* (2012)61 (Pt 1): 23-30. doi: 10.1099/jmm.0.027052-0

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#)

15. Talebi Bezmin Abadi A, Ghasemzadeh A, Mohabati Mobarez A. Low frequency of cagA-positive *Helicobacter pylori* strains isolated from Iranian

patients with MALT lymphoma. *Intern Emerg Med* (2013)8 (1): 49-53. doi: 10.1007/s11739-011-0579-6

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#)

16. Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, et al. Clarithromycin as monotherapy for eradication of *Helicobacter pylori*: a randomized, double-blind trial. *Am J Gastroenterol* (1993)88 (11): 1860-4.

[Pubmed Abstract](#) | [Pubmed Full Text](#)

17. Walsh JH, Peterson WL. The treatment of *Helicobacter pylori* infection in the management of peptic ulcer disease. *N Engl J Med* (1995)333 (15): 984-91. doi: 10.1056/NEJM199510123331508

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#)

18. Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory *Helicobacter pylori* infection: a multicentre clinical trial. *J Antimicrob Chemother* (2013)68 (2): 450-6. doi: 10.1093/jac/dks407

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#)